Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 18B (SCARNA18B) is a member of the scaRNA family, which are small non-coding RNAs that accumulate in Cajal bodies—nuclear sub-organelles implicated in the post-transcriptional modification of spliceosomal RNAs. scaRNAs serve as guide RNAs for the site-specific 2′-O-methylation and pseudouridylation of small nuclear RNAs (snRNAs) involved in pre-mRNA splicing[1][3][5][4]. This molecule is not a receptor, enzyme, transporter, or conventional drug target, and currently has no direct implication in drug interactions, disease mechanisms, or biomarker roles. Its primary function relates to the maturation of snRNAs within the Cajal body.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small Cajal body-specific RNA 18B (SCARNA18B).